Skip to main content

Advertisement

SpringerLink
Log in

Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bendtzen K (2003) Anti-IFN BAb and NAb antibodies; a minireview. Neurology 61:S6–S10

    Article  PubMed  Google Scholar 

  2. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T (1999) Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52:1239–1243

    PubMed  CAS  Google Scholar 

  3. Giovannoni G, Goodman A (2005) Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice? Neurology 65:6–8

    Article  PubMed  Google Scholar 

  4. Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A (2004) Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 62:2031–2037

    PubMed  CAS  Google Scholar 

  5. Pachner A, Dail D, Pak E, Narayan K (2005) The importance of measuring IFNβ bioactivity: monitoring in MS patients and the effect of anti-IFNβ antibodies. J Neuroimmunol 166:180–188

    Article  PubMed  CAS  Google Scholar 

  6. Pachner A, Narayan K, Price N, Hurd M, Dail D (2003) MxA Gene Expression Analysis as an Interferon-beta Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity. Mol Diagn 7:17–25

    Article  PubMed  Google Scholar 

  7. Pachner AR (2003) An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 61:1444–1446

    PubMed  CAS  Google Scholar 

  8. Pachner AR (2007) Neutralizing anti-IFNbeta antibodies: clarity and confusion. Mult Scler 13:1081–1082

    Article  PubMed  CAS  Google Scholar 

  9. Pachner AR, Bertolotto A, Deisenhammer F (2003) Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: Detection of antibody-mediated decreased bioactivity (ADB). Neurology 61:S24–S26

    PubMed  CAS  Google Scholar 

  10. Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E, Fantozzi R, Galgani S, Pasqualetti P, Millefiorini E, Spadaro M, Dahlke F, Gasperini C (2002) Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. J Neurol 249:50–56

    Article  PubMed  CAS  Google Scholar 

  11. Soelberg Sorensen P, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K (2005) Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65:33–39

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Neurology and Neurosciences, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, 185 S. Orange Ave., Newark, NJ, 07103, USA

    Andrew R. Pachner M.D., Jennifer Brady B.S. & Kavitha Narayan M.S.

  2. Hebrew University, Jerusalem, Israel

    Israel Steiner M.D.

Authors
  1. Andrew R. Pachner M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Brady B.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Israel Steiner M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kavitha Narayan M.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew R. Pachner M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pachner, A.R., Brady, J., Steiner, I. et al. Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients. J Neurol 255, 1815–1817 (2008). https://doi.org/10.1007/s00415-008-0854-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-008-0854-2

Keywords

Search

Navigation